CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

• Main Authors: ISHIGURO TAKAHIRO, SHU WEN SAMANTHA HO, HOSHINO MAYUMI, RUIKE YOSHINAO, AIDA SATOSHI, LEE SHUET THENG, KAWAI YUMIKO
• Format: Patent
• Language: English; Japanese
• Published: 05.09.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide multispecific antigen-binding molecules comprising a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, and to provide uses of such multispecific antigen-binding molecules, and the like.SOLUTION: The present invention relates to novel multispecific antigen-binding molecules comprising a first antigen-binding domain with RNF43-binding activity and a second antigen-binding domain with T-cell receptor complex-binding activity and having excellent cytotoxicity and high stability. Since the molecules of the present invention exhibit strong cytotoxicity against cells and tissues expressing RNF43, they are possible to produce novel pharmaceutical compositions containing multispecific antigen-binding molecules for treating or preventing various cancers.SELECTED DRAWING: None 【課題】本発明は、RNF43結合活性を有する第1抗原結合ドメインとT細胞受容体複合体結合活性を有する第2抗原結合ドメインとを含む多重特異性抗原結合分子、そのような多重特異性抗原結合分子の使用等を提供する。【解決手段】本発明は、RNF43結合活性を有する第1抗原結合ドメインとT細胞受容体複合体結合活性を有する第2抗原結合ドメインとを含む、細胞傷害性が優れかつ安定性が高い、新規な多重特異性抗原結合分子に関する。本発明の分子は、RNF43を発現する細胞および組織に対して強力な細胞傷害性を示すため、様々ながんを治療または予防するための、多重特異性抗原結合分子を含む新規な薬学的組成物を製造することが可能である。【選択図】なし